A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

By sjmartinez • April 30, 2024

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23. PMID: 38261444.

Tags: Dermatology, Hematology/Oncology, melanoma, mitogen‐activated protein kinase, nonsmall cell lung cancer, papillary thyroid carcinoma, phosphatidylinositol‐3' kinases, proto‐oncogene proteins B‐RAF, Publications

Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

Wang CJ, Bang A, Chowdhury S, Leslie KS, Lang UE, Shimoda M, Henrich TJ, Hoh R, Deeks SG, Wang C, Deitchman AN, Couey P, Maurer[...]

Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer

Jung SY, Pellegrini M, Tan X, Yu H. Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer. Aging (Albany NY). 2025[...]

Macrophage-derived Spp1 promotes intramuscular fat in dystrophic muscle

Farahat PK, Kumagai-Cresse C, Aragón RL, Ma F, Amakor JK, Espinoza A, Kramerova I, Jimenez RJ, Smith BM, Perez J, Crosbie RH, Nagendra AH, McCourt-Towner[...]